Subgrouping of intermediate-stage (BCLC stage B) hepatocellular carcinoma based on tumor number and size and Child–Pugh grade correlated with prognosis after transarterial chemoembolization

@article{Yamakado2014SubgroupingOI,
  title={Subgrouping of intermediate-stage (BCLC stage B) hepatocellular carcinoma based on tumor number and size and Child–Pugh grade correlated with prognosis after transarterial chemoembolization},
  author={Koichiro Yamakado and Shiro Miyayama and Shozo Hirota and Kimiyoshi Mizunuma and Kenji Nakamura and Yoshitaka Inaba and Hiroaki Maeda and Kunihiro Matsuo and Norifumi Nishida and Takeshi Aramaki and Hiroshi Anai and Shinichi Koura and Shigeo Oikawa and Ken Watanabe and Taku Yasumoto and Kinya Furuichi and Masato Yamaguchi},
  journal={Japanese Journal of Radiology},
  year={2014},
  volume={32},
  pages={260-265}
}
To find a subgroup that benefits most from transarterial chemoembolization (TACE) in terms of tumor number and size and liver profile in patients with intermediate-stage hepatocellular carcinoma (HCC). Data of 325 intermediate-stage HCC patients who received TACE as the initial treatment were gathered. Four tumor numbers (3–6 tumors) and five maximum tumor diameters (3–7 cm) as well as all of their combinations but one (3 tumors and 3 cm) and Child–Pugh grade were used as variables to ascertain… CONTINUE READING